ICICI Securities's research report on Clean Science and Technology
Clean Science’s (CST) performance was impacted from a dip in volumes owing to demand headwinds and a Chinese customer backward integrating. CST anticipates a muted Q3FY26 and a recovery emerging in Q4FY26 along with a rise in off-take for new products, including barbituric acid, performance chemical-1 and DHDT. The company is open to supporting its customers by cutting prices, and thereby, making them competitive against Chinese supplies in the end-market; it prioritises retaining leadership and market share. HALS performance has shown improvement with a consistent rise in volumes and improvement in gross profit margins.
Outlook
We cut our FY26–27E EPS by 16–19% and TP to INR 930 (vs. INR 1,330) with a FY27E P/E multiple of 30x (35x earlier). We upgrade to HOLD (from Reduce) and anticipate a recovery only in FY27.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.